Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 6/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.39 |
| ▸ | PDE4A | P27815 | 3/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.38 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.38 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.38 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.38 |
| ▸ | MMP12 | P39900 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10185635 | 0.89 | NAMPT (0.45) | ARPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL10184449 | 0.89 | L3MBTL1 (0.51) | L3MBTL1CHRNA7ARDGAT1SOAT1 | |
| SCHEMBL10185399 | 0.88 | L3MBTL1 (0.49) | L3MBTL1CHRNA7DGAT1SOAT1MMP12 | |
| SCHEMBL10185769 | 0.88 | L3MBTL1 (0.49) | L3MBTL1CHRNA7ARDGAT1SOAT1 | |
| SCHEMBL10185384 | 0.87 | CHRNA7 (0.42) | CHRNA7ARPDE4DPDE4APDE4B | |
| SCHEMBL10185381 | 0.85 | UTS2R (0.47) | CHRNA7PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL10185102 | 0.85 | UTS2R (0.42) | CHRNA7ARPDE4DPDE4APDE4B | |
| SCHEMBL10185773 | 0.84 | L3MBTL1 (0.51) | L3MBTL1CHRNA7DGAT1SOAT1MMP12 | |
| SCHEMBL10185719 | 0.83 | UTS2R (0.46) | CHRNA7AR | |
| SCHEMBL10186252 | 0.83 | LMNA (0.47) | ARMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
| WO-2010122968-A1 | DIACYLETHYLENEDIAMINE COMPOUND | アステラス製薬株式会社 (JP) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | DGAT1, DGAT2, DIMT1 | L3MBTL1 607/4885CHRNA7 4193/4885AR 4039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.